September 2026 Research Update

This month added a clearer picture of what adult LCH treatment can look like in real life: many people receive established chemotherapy regimens, and reports described disease responses, while supportive care aimed at bone health showed measurable short-term changes. The evidence is a mix of routine-care data and an uncontrolled supportive-care study, so it describes what happened rather than proving what works best. Still, the studies help connect treatment choices to the kinds of outcomes that were tracked, such as overall treatment response, time without worsening, pain, and bone markers. [1] [2]

In a single-center cohort of 18 adults with non-pulmonary LCH, most received systemic treatment and the group had a reported overall response rate of 78%, with a median progression-free survival of 34 months (overall survival was not reached during follow-up). Multisystem disease and bone involvement were common, and diabetes insipidus was present in 4 people, showing that endocrine problems can be part of adult LCH alongside other organ involvement. BRAF V600E was positive in 20% of those tested, highlighting that not all adult LCH is driven by this mutation. [1]

A separate adult study focused on bone health rather than anti-LCH drugs: 45 adults received cholecalciferol (vitamin D3) supplementation for 3 months with the goal of raising vitamin D levels. Vitamin D levels increased and parathyroid hormone decreased, and a blood marker of bone breakdown (CTX) went down, alongside improvements in certain pain and daily-function quality-of-life areas. Because there was no comparison group, the results show changes over time during supplementation, but they cannot confirm vitamin D as the reason those changes happened. [2]

For patients and caregivers, these studies mainly add context about what outcomes have been reported in adults receiving commonly used LCH regimens and what kinds of supportive care questions are being studied. The cohort report may matter now as a realistic snapshot of treatment patterns and longer-term tracking (months to years), but it does not compare one regimen against another. The vitamin D study may matter now mainly as an early signal that bone-related lab markers and some quality-of-life areas can change over a few months when vitamin D levels rise, but it remains uncertain how much of this is directly caused by supplementation or how durable the changes are. [1] [2]

This month, several studies pointed toward more refined ways to confirm LCH and to estimate who may be at higher risk of worsening or relapse. The pattern across studies was that tests are being used for different jobs: some help find and biopsy unusual lesions, while others aim to predict future course. Most of this work is still early, but it makes the testing landscape feel less one-size-fits-all and more tailored to specific LCH situations. [3] [4] [5] [6]

In 32 newly diagnosed children, baseline FDG-PET/CT measures were linked with later progression or relapse, but involvement of high-risk organs was the strongest predictor. Higher PET/CT activity measures (such as SUVmax and tumor-to-background ratio) were also reported more often in those who progressed or relapsed. This supports the idea that both which organs are involved and how "metabolically active" lesions look on PET/CT may relate to how the disease behaves over time. [3]

Another study focused on LCH-related neurodegeneration, using spinal fluid and blood testing to look for markers that separate neurodegenerative LCH from other LCH groups. A spinal-fluid protein called IL-1RT2 (described as a decoy receptor) was reported as highly able to distinguish neurodegenerative LCH from non-neurodegenerative LCH in this dataset, and it decreased during treatment in some people followed over time. Blood neurofilament light chain (NFL), a general marker of nerve cell injury, was also elevated in adults with histiocytosis-associated neurodegeneration, including some already on BRAF or MEK inhibitors. [4]

Two reports highlighted diagnosis in uncommon locations where LCH can be missed. In an 11-year-old with isolated liver LCH, contrast-enhanced ultrasound showed a rim-enhancing nodule pattern that the authors felt could help target biopsy alongside CT or MRI, while still requiring tissue confirmation. In a separate institutional review of thyroid needle biopsies, LCH appeared as 1 of 9 first-time blood-related diagnoses found in thyroid samples over 4 years, underscoring that needle biopsy can sometimes detect LCH even when the thyroid is the presenting site. [5] [6]

For families, these studies may matter in two ways: they describe how newer testing approaches might help clarify what is going on, and they hint at how tests might help anticipate risk. The pediatric PET/CT study may matter now because it reinforces that risk-organ involvement is a major warning sign, and it suggests PET/CT activity measures could add more detail, although this was one retrospective group. The neurodegeneration biomarker work is mainly research for now, but it helps clarify that neurodegenerative LCH may have a measurable spinal-fluid signal (IL-1RT2) and a blood signal (NFL) that could someday help with earlier recognition and tracking response, while it remains uncertain how specific IL-1RT2 is compared with other brain diseases. The liver ultrasound and thyroid biopsy reports are early signals that diagnosis in unusual sites may be supported by targeted imaging and careful pathology review, but single-center and single-patient reports cannot tell how often these approaches will help. [3] [4] [5] [6]

The case reports this month reinforced that LCH can look very different from person to person, and that delays or detours in diagnosis can happen when disease shows up in unusual organs. Across these reports, biopsy with the usual LCH markers (such as CD1a, S100, and langerin) was the step that confirmed the diagnosis. The reports also showed that treatment and follow-up are highly individualized, ranging from local skin care to multi-drug chemotherapy, depending on whether disease is isolated or multisystem. [7] [8] [9] [10] [11] [12]

Several reports highlighted isolated or localized disease that improved without intensive systemic therapy. One adult with vulvar and skin-fold erosions had no disease outside the skin on staging and improved markedly over 1 year with topical clobetasol and local wound care. Another adult with an isolated gastric lesion had LCH markers on biopsy and BRAF V600E positivity by immunohistochemistry, with stable findings and symptom resolution on follow-up under surveillance. [8] [11]

Other reports emphasized multisystem or complex organ involvement, where diagnosis and treatment were more intensive. A 44-year-old woman had LCH recognized late after starting with central diabetes insipidus, and testing found a MAP2K1 mutation without BRAF V600E; after cytarabine and later salvage chemotherapy that included denosumab, imaging showed complete response in some lesions with partial response or stability in others. In a separate pediatric liver case that initially resembled Caroli syndrome, LCH was only diagnosed on the removed liver after transplantation, and later recurrence in the transplanted liver improved clinically with vincristine plus prednisone and partial imaging regression. [7] [9]

Two additional reports focused on diagnostic challenges in hard-to-recognize locations. A pediatric clival (skull-base) lesion looked like a more aggressive tumor on imaging, but most published cases had good outcomes, with no recurrences reported during follow-up, after varied management approaches. A pulmonary LCH case in a smoker described confirmation using surgical lung and rib biopsies after imaging showed lung nodules and a rib lesion, illustrating how tissue diagnosis may be pursued when less invasive tests are limited. [10] [12]

One small series looked at day-to-day behavioral effects when LCH involves the cerebellum, the part of the brain involved in coordination and some behavior networks. More extensive cerebellar and brainstem changes were linked with more severe impulsive, compulsive, or socially inappropriate behaviors, while more limited findings were linked with milder attention and impulse symptoms. In one patient, worsening behavior tracked with cerebellar lesion progression and later improved after immunomodulatory treatment, showing how symptoms and brain changes may move together in some people. [13]

For patients and caregivers, these reports mainly help set expectations about the range of ways LCH can appear and why careful staging and biopsy matter. They do not prove that any one approach is best, but they clarify that LCH can be confined to one site (like skin or stomach) or can involve many organs with mixed responses across lesions. They also highlight that certain molecular findings (such as MAP2K1 mutation or BRAF V600E by immunohistochemistry) may be identified in individual patients, although what to do with that information depends on broader evidence that is still limited in adults. The neuropsychiatric series may matter now as an explanation for how cerebellar involvement can relate to behavior changes, while it remains uncertain how often this pattern occurs and which treatments reliably improve it. [8] [11] [7] [9] [10] [12] [13]